MA51938B1 - Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn - Google Patents
Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arnInfo
- Publication number
- MA51938B1 MA51938B1 MA51938A MA51938A MA51938B1 MA 51938 B1 MA51938 B1 MA 51938B1 MA 51938 A MA51938 A MA 51938A MA 51938 A MA51938 A MA 51938A MA 51938 B1 MA51938 B1 MA 51938B1
- Authority
- MA
- Morocco
- Prior art keywords
- rna
- compositions
- methods
- splicing
- interfering rna
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000005856 abnormality Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 230000002452 interceptive effect Effects 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 3
- 101100063539 Mus musculus Dmpk gene Proteins 0.000 abstract 2
- 239000013603 viral vector Substances 0.000 abstract 2
- 206010068871 Myotonic dystrophy Diseases 0.000 abstract 1
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 abstract 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 abstract 1
- 102000015097 RNA Splicing Factors Human genes 0.000 abstract 1
- 108010039259 RNA Splicing Factors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des compositions et des procédés pour le traitement de troubles associés à l'épissage incorrect d'acide ribonucléique (arn), notamment des troubles caractérisés par la rétention nucléaire de transcrits d'arn contenant des régions répétées étendues de manière aberrante qui lient et séquestrent des protéines de facteur d'épissage. L'invention concerne des constructions d'arn interférant qui suppriment l'expression de transcrits d'arn contenant des régions répétées étendues, ainsi que des vecteurs viraux, tels que des vecteurs viraux adénoassociés, codant de telles molécules d'arn interférant. Par exemple, l'invention concerne des molécules d'arn interférant, telles que des constructions d'arnsi, de miarn et de sharn, qui s'hybrident à des transcrits d'arn de la protéine kinase de la dystrophie myotonique (dmpk) et atténuent l'expression de l'arn de dmpk contenant des répétitions de trinucléotides cug étendues. En utilisant les compositions et les procédés de l'invention, un patient ayant un trouble de dominance arn, tel qu'un patient humain atteint d'une dystrophie myotonique, parmi d'autres affections décrites ici, peut recevoir une construction d'arn interférant ou un vecteur la contenant afin de réduire l'apparition d'une anomalie d'épissage chez le patient, ce qui permet de traiter une étiologie sous-jacente de la maladie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862671769P | 2018-05-15 | 2018-05-15 | |
PCT/US2019/032423 WO2019222354A1 (fr) | 2018-05-15 | 2019-05-15 | Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn |
Publications (2)
Publication Number | Publication Date |
---|---|
MA51938A1 MA51938A1 (fr) | 2021-11-30 |
MA51938B1 true MA51938B1 (fr) | 2022-10-31 |
Family
ID=68540673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA51938A MA51938B1 (fr) | 2018-05-15 | 2019-05-15 | Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210269825A1 (fr) |
EP (1) | EP3793566A4 (fr) |
JP (1) | JP2021522836A (fr) |
KR (1) | KR20210010549A (fr) |
CN (1) | CN112469421A (fr) |
AU (1) | AU2019268346A1 (fr) |
BR (1) | BR112020023298A2 (fr) |
CA (1) | CA3098249A1 (fr) |
CL (1) | CL2020002955A1 (fr) |
CO (1) | CO2020015239A2 (fr) |
MA (1) | MA51938B1 (fr) |
MX (1) | MX2020012269A (fr) |
PH (1) | PH12020551913A1 (fr) |
SG (1) | SG11202011151VA (fr) |
WO (1) | WO2019222354A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023034870A2 (fr) | 2021-09-01 | 2023-03-09 | Ionis Pharmaceuticals, Inc. | Composés et méthodes pour réduire l'expression de dmpk |
US20230365968A1 (en) * | 2022-04-06 | 2023-11-16 | Genzyme Corporation | Targeted gene therapy for dm-1 myotonic dystrophy |
WO2023220719A2 (fr) * | 2022-05-13 | 2023-11-16 | University Of Washington | Méthode de traitement de la dystrophie myotonique combinant l'expression de protéines et l'administration de vecteurs d'interférence d'arn avec un déciblage tissulaire |
WO2024006770A1 (fr) * | 2022-06-27 | 2024-01-04 | Astellas Gene Therapies, Inc. | Compositions et procédés pour le traitement de dystrophies myotoniques |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977333A (en) * | 1992-02-06 | 1999-11-02 | Massachusetts Institute Of Technology | DNA sequence encoding the myotonic dystrophy gene and uses thereof |
US20050042646A1 (en) * | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
JP6839094B2 (ja) * | 2014-12-24 | 2021-03-03 | ユニクア・アイピー・ベーフェー | RNAiで誘発されるハンチンチン遺伝子抑制 |
US11260073B2 (en) * | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
WO2018064600A1 (fr) * | 2016-09-30 | 2018-04-05 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant une expansion de répétition hexanucléotidique dans un locus c9orf72 |
-
2019
- 2019-05-15 MX MX2020012269A patent/MX2020012269A/es unknown
- 2019-05-15 AU AU2019268346A patent/AU2019268346A1/en active Pending
- 2019-05-15 BR BR112020023298-0A patent/BR112020023298A2/pt not_active Application Discontinuation
- 2019-05-15 WO PCT/US2019/032423 patent/WO2019222354A1/fr unknown
- 2019-05-15 US US17/054,474 patent/US20210269825A1/en active Pending
- 2019-05-15 CA CA3098249A patent/CA3098249A1/fr active Pending
- 2019-05-15 EP EP19803882.0A patent/EP3793566A4/fr active Pending
- 2019-05-15 KR KR1020207036197A patent/KR20210010549A/ko unknown
- 2019-05-15 SG SG11202011151VA patent/SG11202011151VA/en unknown
- 2019-05-15 CN CN201980047374.XA patent/CN112469421A/zh active Pending
- 2019-05-15 JP JP2020563947A patent/JP2021522836A/ja active Pending
- 2019-05-15 MA MA51938A patent/MA51938B1/fr unknown
-
2020
- 2020-11-10 PH PH12020551913A patent/PH12020551913A1/en unknown
- 2020-11-13 CL CL2020002955A patent/CL2020002955A1/es unknown
- 2020-12-03 CO CONC2020/0015239A patent/CO2020015239A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PH12020551913A1 (en) | 2021-06-14 |
KR20210010549A (ko) | 2021-01-27 |
US20210269825A1 (en) | 2021-09-02 |
AU2019268346A1 (en) | 2020-12-24 |
MX2020012269A (es) | 2021-04-28 |
SG11202011151VA (en) | 2020-12-30 |
CL2020002955A1 (es) | 2021-04-23 |
CO2020015239A2 (es) | 2021-03-08 |
MA51938A1 (fr) | 2021-11-30 |
CN112469421A (zh) | 2021-03-09 |
BR112020023298A2 (pt) | 2021-03-09 |
EP3793566A1 (fr) | 2021-03-24 |
CA3098249A1 (fr) | 2019-11-21 |
JP2021522836A (ja) | 2021-09-02 |
WO2019222354A1 (fr) | 2019-11-21 |
EP3793566A4 (fr) | 2022-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51938B1 (fr) | Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn | |
Willem et al. | η-Secretase processing of APP inhibits neuronal activity in the hippocampus | |
Wootz et al. | Alterations in the motor neuron–renshaw cell circuit in the Sod1G93A mouse model | |
Capo et al. | Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer’s disease patients | |
EP3881859B1 (fr) | Compositions pour augmenter la neurogenèse et l'angiogenèse | |
Seyrantepe et al. | Intracerebral gene therapy in children with metachromatic leukodystrophy: Results of a phase I/II trial | |
Chelluboina et al. | Mesenchymal stem cell treatment prevents post-stroke dysregulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases | |
EP1074616A1 (fr) | Procédé pour la purification de la protéase qui active le facteur VII, de son proenzyme, ou d'un mélange des deux, par chromatographie d'échange ionique | |
Tang et al. | A case of mistaken identity: The MAR-1 antibody to mouse FcεRIα cross-reacts with FcγRI and FcγRIV | |
Szczepanska-Sadowska et al. | Multiple aspects of inappropriate action of renin–angiotensin, vasopressin, and oxytocin systems in neuropsychiatric and neurodegenerative diseases | |
Freemantle et al. | Cholesterol and phospholipids in frontal cortex and synaptosomes of suicide completers: relationship with endosomal lipid trafficking genes | |
EP2970468B1 (fr) | Molécules de liaison à notch2 pour le traitement de maladies respiratoires | |
Xia et al. | Genome-wide RNA sequencing analysis reveals that IGF-2 attenuates memory decline, oxidative stress and amyloid plaques in an Alzheimer’s disease mouse model (AD) by activating the PI3K/AKT/CREB signaling pathway | |
Li et al. | Immunohistochemical distribution of S-100 protein in the cerebral cortex with regard to the cause of death in forensic autopsy | |
JP2022166193A (ja) | インターフェロンレベルを低下させるのに有用な化合物 | |
AR078734A1 (es) | Composiciones, metodos para el tratamiento, y diagnostico de trastornos relacionados con la autoinmunidad y metodos para preparar tales composiciones | |
Fencl et al. | Discordant expression of a new WT1 gene mutation in a family with monozygotic twins presenting with congenital nephrotic syndrome | |
JP2020505446A (ja) | リソソーム蓄積症およびリソソーム蓄積障害を処置するための組成物および方法 | |
DE112012000439T5 (de) | Stammzellfaktor-Inhibitor | |
DE60012140T2 (de) | Verwendung von urintrypsininhibitor zur diagnose von aids | |
Hattori et al. | Increase of integrin-linked kinase activity in cultured podocytes upon stimulation with plasma from patients with recurrent FSGS | |
De Gasperi et al. | Peripheral myelin protein-22 is expressed in CNS myelin | |
CN108042790B (zh) | 一种五肽KLPGF抑制AChE活性的应用 | |
Gosemann et al. | Increased activation of NADPH oxidase 4 in the pulmonary vasculature in experimental diaphragmatic hernia | |
Eric Matamoros | GcMAF: a polemic or a highly promising molecule? |